Krystal Biotech(KRYS.US)

Last Updated 19:00:00 ET
longbridge loading

Corbus Pharma names Nishant Saxena chief business officer

PUBT·
US
CRBP
+14.29%
US
KRYS
+0.91%
US
XLV
+0.61%
PUBT·
US
CRBP
+14.29%
US
KRYS
+0.91%
US
XLV
+0.61%

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

Fidelity·
US
KRYS
+0.91%
Fidelity·
US
KRYS
+0.91%

Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week High - Here's Why

Market Beat·
US
KRYS
+0.91%
US
IBB
+0.72%
US
IBBQ
+0.69%
Market Beat·
US
KRYS
+0.91%
US
IBB
+0.72%
US
IBBQ
+0.69%

HC Wainwright Expects Increased Earnings for Krystal Biotech

Market Beat·
US
KRYS
+0.91%
US
ARKG
+3.05%
US
IHE
+0.86%
Market Beat·
US
KRYS
+0.91%
US
ARKG
+3.05%
US
IHE
+0.86%

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

benzinga_article·
US
KRYS
+0.91%
US
BBH
+0.85%
US
IXJ
+0.60%
benzinga_article·
US
KRYS
+0.91%
US
BBH
+0.85%
US
IXJ
+0.60%

Krystal Biotech Earnings Call Highlights Profitable Growth

Tip Ranks·
US
KRYS
+0.91%
US
PBE
+0.50%
US
BIB
+0.08%
Tip Ranks·
US
KRYS
+0.91%
US
PBE
+0.50%
US
BIB
+0.08%

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Tip Ranks·
US
KRYS
+0.91%
US
LABU
+2.52%
US
BBH
+0.85%
Tip Ranks·
US
KRYS
+0.91%
US
LABU
+2.52%
US
BBH
+0.85%

Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Market Beat·
US
KRYS
+0.91%
US
IBBQ
+0.69%
US
BIB
+0.08%
Market Beat·
US
KRYS
+0.91%
US
IBBQ
+0.69%
US
BIB
+0.08%
© 2026 Longbridge｜Disclaimer